Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Pfizer
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGEAL CANDIDIASIS IN PEDIATRIC SUBJECTS
To assess the safety and tolerability of voriconazole for the treatment of invasive candidiasis, including candidemia, and esophageal candidiasis in pediatric subjects 2 to <18 years of age.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd
MAJ Il y a 5 ans
A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY
• To evaluate the efficacy of [S,S]-RBX in patients with DPN • To evaluate the safety and tolerability of [S,S]-RBX in patients with DPN
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Hellas AE
MAJ Il y a 5 ans
A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
The primary objective of this study is to evaluate change in weight as a result of switching to ziprasidone, in subjects who have failed to achieve a satisfactory clinical response to quetiapine due t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer, S. A
MAJ Il y a 5 ans
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
To determine the antitumor efficacy of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks repeated every 6 weeks in patients having metastatic NSCLC who have previously...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 5 ans
A study to evaluate the pharmacokinetics (the way the body absorbs, distributes and eliminates the drug) of the study drug pantoprazole in hospitalized children aged 1-16 years old who are candidates for acid suppression therapy
To characterize the PK profile of single and repeated IV doses of pantoprazole in pediatric subjects aged 1 to less than 2 years old. To characterize the PK profile of single and repeated IV doses...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF UK-453,061, IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE VERSUS EFAVIRENZ IN COMBINATION WITH TENOFOVIR DF AND EMTRICITABINE FOR THE TREATMENT OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED SUBJECTS
The primary objective is to assess efficacy of UK-453,061 when used in combination with tenofovir DF/emtricitabine, as measured by percentage of subjects with HIV-1 RNA <48 copies/mL at 48 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
PHASE II OPEN LABEL, MULTICENTER, PROSPECTIVE,RELATED MACULAR DEGENERATION, COMPARATOR STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET STUDY)
To evaluate the efficacy of different dosing paradigms of PF-04523655 versus ranibizumab (comparator) in subjects with neovascular AMD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Pfizer Ltd, Ramsgate Road, Sandwich, Kent. UK
MAJ Il y a 5 ans
A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)
Estimate the efficacy of UK-369,003 MR versus placebo for the treatment of storage male LUTS with and without ED.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
MAJ Il y a 5 ans
OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN THIS POPULATION
To raise awareness and enhance the diagnosis of patients with chronic low back pain(CLBP) with a neuropathic pain component who are refractory to standard analgesic therapy and/or one treatment for ne...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003
The primary objective of this study is to evaluate the long term safety, tolerability, and immunogenicity of PF-04236921.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant